

Date 06/02/2026  
Your Ref  
Our Ref 11037

Enquiries to Richard Mutch  
Extension 35687  
Direct Line 0131 465 5687  
[loth.freedomofinformation@nhs.scot](mailto:loth.freedomofinformation@nhs.scot)  
[richard.mutch@nhs.scot](mailto:richard.mutch@nhs.scot)

Dear

## FREEDOM OF INFORMATION – MULTIPLE SCLEROSIS

I write in response to your request for information in relation to Multiple Sclerosis prescribing.

### Question:

1. How many patients who have a current diagnosis of Multiple Sclerosis received treatment in the last six months with any of the following treatment regimens (July 2025 – December 2025)?

### Answer

- Ocrevus (ocrelizumab) IV (300mg/30ml) - 275
- Ocrevus (ocrelizumab) Subcutaneous (920mg/23ml) - 0
- Kesimpta (ofatumumab) - 229
- Briumvi (ublituximab) - 21
- Mavenclad (cladribine) - 20
- Dimethyl Fumarate (Tecfidera + Dimethyl Fumarate generic) - 350
- Natalizumab (Tysabri and Tyruko) - 80

### Question:

2. Of the patients identified in question one, how many patients received the same treatment in the previous six-month period? (i.e. How many of the same patients received treatment with each treatment regimen in January 2025 to June 2025 AND July 2025 – December 2025?)
  - Ocrevus (ocrelizumab) IV (300mg/30ml)
  - Ocrevus (ocrelizumab) Subcutaneous (920mg/23ml)
  - Kesimpta (ofatumumab)
  - Briumvi (ublituximab)
  - Mavenclad (cladribine)
  - Dimethyl Fumarate (Tecfidera + Dimethyl Fumarate generic)
  - Natalizumab (Tysabri and Tyruko)

### Answer:

Data not collected. As we do not hold data on the full population of individuals diagnosed with Multiple Sclerosis. We only hold information on patients seen in hospital settings, which does

Headquarters  
Mainpoint  
102 West Port  
Edinburgh EH3 9DN

Chair Professor John Connaghan CBE  
Chief Executive Professor Caroline Hiscox  
*Lothian NHS Board is the common name of Lothian Health Board*

not represent the entire patient population. Providing an answer based on incomplete data would therefore be misleading and potentially biased.

Under the Freedom of Information Act NHS Lothian is not required to create new records to enable it to respond to your enquiry. This information is not collated or held in aggregate form and it would be necessary to review all case files relating to patients over the period you have requested to assemble the information you seek. Even if NHS Lothian did this – and there would be significant cost implications in doing so – it would be unable to respond in full to your request. The information requested is therefore exempt under section 12.1 – Cost.

Question:

3. How many patients have received a new diagnosis for Multiple Sclerosis in the latest six-month period (July 2025 – December 2025)?

Answer:

There were 66 patients.

Question:

4. Of the patients identified in question two, how many of these patients have received any of the following treatment regimens as their first treatment following their Multiple Sclerosis diagnosis?

Answer:

- Ocrevus (ocrelizumab) IV (300mg/30ml) - 5<
- Ocrevus (ocrelizumab) Subcutaneous (920mg/23ml) 0
- Kesimpta (ofatumumab) - 20
- Briumvi (ublituximab) - 12
- Mavenclad (cladribine) - 0
- Dimethyl Fumarate (Tecfidera + Dimethyl Fumarate generic) - 6
- Natalizumab (Tysabri and Tyruko) - 0

To protect the identity of the individuals involved any figure of 5 or less has not been shown in the table above. Since we do not have their consent to release this data from their records, the information is exempt under section 38(1)(b) of the Freedom of Information (Scotland) Act i.e. to provide it would breach the Data Protection Act (2018).

I hope the information provided helps with your request.

If you are unhappy with our response to your request, you do have the right to request us to review it. Your request should be made within 40 working days of receipt of this letter, and we will reply within 20 working days of receipt. If our decision is unchanged following a review and you remain dissatisfied with this, you then have the right to make a formal complaint to the Scottish



Information Commissioner within 6 months of receipt of our review response. You can do this by using the Scottish Information Commissioner's Office online appeals service at [www.itspublicknowledge.info/Appeal](http://www.itspublicknowledge.info/Appeal). If you remain dissatisfied with the Commissioner's response you then have the option to appeal to the Court of Session on a point of law.

If you require a review of our decision to be carried out, please write to the FOI Reviewer at the email address at the head of this letter. The review will be undertaken by a Reviewer who was not involved in the original decision-making process.

FOI responses (subject to redaction of personal information) may appear on NHS Lothian's Freedom of Information website at: <https://org.nhslothian.scot/FOI/Pages/default.aspx>

Yours sincerely

**ALISON MACDONALD**  
**Executive Director, Nursing**  
Cc: Chief Executive